Form D · Pharmaceuticals
TOSK INC
Mountain View, CA · CIK 0001098412
Offering snapshot reported Sep 16, 2022 · SEC filing
- Reported sold
- $100K Offering amount: $3M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $100K Reported outside-investor minimum
- First sale
- Sep 15, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 16, 2022 | Initial | $100,000 | No comparison | 1 | SEC filing |
| Oct 29, 2019 | Amendment | $3,091,524 | $1,572,722vs Jul 2, 2018 | 56 | SEC filing |
| Jul 2, 2018 | Amendment | $1,518,802 | $752,796vs May 26, 2017 | 31 | SEC filing |
| May 26, 2017 | Amendment | $766,006 | $748,006vs Mar 28, 2016 | 18 | SEC filing |
| Mar 28, 2016 | Initial | $18,000 | No comparison | 1 | SEC filing |
| Aug 25, 2014 | Amendment | $5,449,274 | $3,797,684vs May 13, 2013 | 74 | SEC filing |
| May 13, 2013 | Amendment | $1,651,590 | $340,002vs Mar 4, 2013 | 12 | SEC filing |
| Mar 4, 2013 | Amendment | $1,311,588 | $513,588vs Dec 23, 2011 | 10 | SEC filing |
| Dec 23, 2011 | Initial | $798,000 | No comparison | 1 | SEC filing |
| May 5, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-459046
Source: Form D, filed Sep 16, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Harold Crow | Director |
| Brian Frenzel | Executive |
| Charles Garvin | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2672 Bayshore Parkway # 507
Mountain View, CA, 94043
Mountain View, CA, 94043